Literature DB >> 8535663

Successful matched unrelated transplantation from a donor with idiopathic thrombocytopenic purpura (ITP).

M Delukina1, Y Kapelushnik, R Or, E Naparstek, S Slavin, A Nagler.   

Abstract

The case of a 5 year old male is described who had acute myeloblastic leukaemia (AML M5) and was in third remission when he underwent an allogeneic T cell depleted bone marrow transplantation (BMT). The bone marrow was from an HLA matched unrelated donor (MUD) who suffered from chronic idiopathic thrombocytopenic purpura (ITP). In spite of this, the patient had rapid platelet engraftment post BMT (> 50 x 10(9) l-1 on day 20). He is now 12 months post-transplantation and has normal platelet counts, without any clinical or laboratory evidence of ITP. Autoimmune manifestations such as ITP occurring in bone marrow recipients following BMT have been previously reported. Furthermore, severe and protracted thrombocytopenia is a known complication following MUD transplantation and with its respective high risk of graft versus host disease (GVHD). In this case, no signs of ITP could be detected in the recipient despite the fact that the donor had ITP. Our data suggest that in the absence of an alternative choice, a person with ITP should be considered as an appropriate donor for transplantation.

Entities:  

Mesh:

Year:  1995        PMID: 8535663     DOI: 10.1007/bf01676714

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  17 in total

1.  Autoimmunity and allogeneic bone marrow transplantation.

Authors:  A M Marmont
Journal:  Bone Marrow Transplant       Date:  1992-01       Impact factor: 5.483

2.  Autoimmune thrombocytopenia after allogeneic bone marrow transplantation: a case report.

Authors:  N Katayama; K Oda; I Furuta; N Shimizu; C Ohta; E Tatsumi; N Minami; S Shirakawa
Journal:  Nihon Ketsueki Gakkai Zasshi       Date:  1988-02

Review 3.  Graft-versus-host disease: allo- and autoimmunity after bone marrow transplantation.

Authors:  H M Shulman; K M Sullivan
Journal:  Concepts Immunopathol       Date:  1988

4.  Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin.

Authors:  C I Smith; J A Aarli; P Biberfeld; P Bolme; B Christensson; G Gahrton; L Hammarström; A K Lefvert; B Lönnqvist; G Matell
Journal:  N Engl J Med       Date:  1983-12-22       Impact factor: 91.245

5.  Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.

Authors:  D M Karussis; U Vourka-Karussis; D Lehmann; H Ovadia; R Mizrachi-Koll; A Ben-Nun; O Abramsky; S Slavin
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

6.  Autoimmune thrombocytopenia acquired from an allogeneic bone-marrow graft.

Authors:  R M Minchinton; A H Waters; J Kendra; A J Barrett
Journal:  Lancet       Date:  1982-09-18       Impact factor: 79.321

7.  Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years.

Authors:  D I Marks; J O Cullis; K N Ward; S Lacey; R Syzdlo; T P Hughes; A P Schwarer; E Lutz; A J Barrett; J M Hows; J R Batchelor; J M Goldman
Journal:  Ann Intern Med       Date:  1993-08-01       Impact factor: 25.391

8.  Platelet- and granulocyte-specific antibodies after allogeneic and autologous bone marrow grafts.

Authors:  R M Minchinton; A H Waters; J S Malpas; I Starke; J R Kendra; A J Barrett
Journal:  Vox Sang       Date:  1984       Impact factor: 2.144

9.  Graft-v-host disease is associated with autoimmune-like thrombocytopenia.

Authors:  C Anasetti; W Rybka; K M Sullivan; M Banaji; S J Slichter
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

10.  Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes.

Authors:  L R First; B R Smith; J Lipton; D G Nathan; R Parkman; J M Rappeport
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.